Delving into the Latest Updates on ChAd-triCoV/Mac(McMaster University) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target

SARS-CoV-2 N protein x SARS-CoV-2 S protein

Mechanism

SARS-CoV-2 N protein inhibitors(SARS-CoV-2 N protein inhibitors), SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

COVID-19

Inactive Indication-

Originator Organization

McMaster University

Active Organization

McMaster University

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to study the safety of a new inhaled vaccine to prevent COVID infection and learn about the immune responses that are made in the lungs and the blood after vaccination. Participants will be randomized (like the toss of a coin) to receive the experimental vaccine or a placebo (a look-alike solution that contains no vaccine).
To be in the study participants will have to have already had three doses of a messenger ribonucleic acid (mRNA) COVID vaccine and be generally healthy. Participants are given a single dose of the vaccine by breathing in a fine mist that goes directly into the lungs.
During follow-up participants will:
* visit the clinic for checkups and blood tests at 2, 4 and 8 weeks after vaccination
* report their symptoms for 24 weeks after getting the vaccine.
In some participants, the researchers will collect cells from the lung 4 weeks after vaccination (a test known as a bronchoscopy).

Start Date01 Jan 2025

Sponsor / Collaborator

McMaster University

[+1]

NCT05094609 / Active, not recruitingPhase 1IIT

Phase 1, Open Label Study to Evaluate the Safety and Immunogenicity of ChAd68 and AdHu5 Vector-based Trivalent COVID-19 Vaccines Delivered Via Inhaled Aerosol

This is a phase 1 study in healthy volunteers who have received at least three doses of an mRNA COVID-19 vaccine, to evaluate the safety and immune responses that develop in the blood and lungs following the administration by aerosol of either Ad5-triCoV/Mac or ChAd-triCoV/Mac, new experimental adenovirus-based vaccines expressing SARS-CoV-2 spike, nucleocapsid and RNA polymerase proteins.

Start Date03 Jan 2022

Sponsor / Collaborator

McMaster University

[+1]

100 Clinical Results associated with ChAd-triCoV/Mac(McMaster University)

Login to view more data

100 Translational Medicine associated with ChAd-triCoV/Mac(McMaster University)

Login to view more data

100 Patents (Medical) associated with ChAd-triCoV/Mac(McMaster University)

Login to view more data

4

Literatures (Medical) associated with ChAd-triCoV/Mac(McMaster University)

01 Jan 2024·Asian Pacific journal of allergy and immunology

Humoral and cellular immune responses against SARS-CoV-2 variants of concern induced by heterologous CoronaVac/ChAdOx-1 versus homologous ChAdOx-1 vaccination in the elderly

Article

Author: Inchai, Juthamas ; Niyatiwatchanchai, Nutchanok ; Liwsrisakun, Chalerm ; Tajarernmuang, Pattraporn ; Duangjit, Pilaiporn ; Laopajon, Witida ; Trongtrakul, Konlawij ; Takheaw, Nuchjira ; Kasinrerk, Watchara ; Pothirat, Chaicharn ; Theerakittikul, Theerakorn ; Chaiwong, Warawut ; Pata, Supansa ; Cheyasawan, Passaworn ; Limsukon, Atikun ; Deesomchok, Athavudh ; Chuensirikulchai, Kantinan ; Bumroongkit, Chaiwat

BACKGROUND:

The concept of heterologous vaccination against SARS-CoV-2 infection has been adopted in Thailand with limited data on the induction of humoral and cellular immunity, particularly the CoronaVac/ChAdOx-1 (CoVac/ChAd) regimen in the elderly.

OBJECTIVE:

In this study, the immune responses of the elderly induced by heterologous CoVac/ChAd and homologous ChAdOx-1 (ChAd/ChAd) vaccinations were demonstrated.

METHODS:

A prospective observational study involving healthy participants aged ≥ 60 years who received heterologous CoVac/ChAd or homologous ChAd/ChAd vaccination was conducted. Surrogate neutralizing antibody (NAb) and T-cell responses against the SARS-CoV-2 wild type (WT) and variants of concern were determined at pre and post vaccinations.

RESULTS:

At 4 and 12 weeks after heterologous or homologous vaccination, the NAb levels against WT, Alpha, Beta, and Delta variants between each group were not significantly different, except for significant lower NAb against the Beta variant in heterologous group at 12 weeks after vaccination. The NAb against the Omicron at 4 weeks post-vaccination were below the cutoff level for antibody detection in both groups. However, higher spike-specific CD4 T cell producing IFN-γ and TNF-α in the heterologous than the homologous vaccination were observed. Insignificant difference of cellular immune responses to spike-peptides of Alpha, Beta, and Delta variants and their WT homologues was demonstrated.

CONCLUSIONS:

In the elderly, heterologous CoVac/ChAd vaccination could induce NAb response against the WT and non-Omicron variants not different from the homologous ChAd/ChAd vaccination. Both regimens could not give adequate NAb of the Omicron strain. The heterologous vaccination, however, induced higher spike-specific Th1 cell response.

13 May 2023·Viruses

Comparing Heterologous and Homologous COVID-19 Vaccination: A Longitudinal Study of Antibody Decay.

Article

Author: Carlotti, Eugenio ; Stefanetti, Giuseppe ; Orlandi, Chiara ; Barocci, Simone ; Vandini, Daniela ; Peluso, Sara ; Diotallevi, Aurora ; Galluzzi, Luca ; Buffi, Gloria ; Magnani, Mauro ; Ceccarelli, Marcello ; Rocchi, Ettore ; Casabianca, Anna

The humoral response after vaccination was evaluated in 1248 individuals who received different COVID-19 vaccine schedules. The study compared subjects primed with adenoviral ChAdOx1-S (ChAd) and boosted with BNT162b2 (BNT) mRNA vaccines (ChAd/BNT) to homologous dosing with BNT/BNT or ChAd/ChAd vaccines. Serum samples were collected at two, four and six months after vaccination, and anti-Spike IgG responses were determined. The heterologous vaccination induced a more robust immune response than the two homologous vaccinations. ChAd/BNT induced a stronger immune response than ChAd/ChAd at all time points, whereas the differences between ChAd/BNT and BNT/BNT decreased over time and were not significant at six months. Furthermore, the kinetic parameters associated with IgG decay were estimated by applying a first-order kinetics equation. ChAd/BNT vaccination was associated with the longest time of anti-S IgG negativization and with a slow decay of the titer over time. Finally, analyzing factors influencing the immune response by ANCOVA analysis, it was found that the vaccine schedule had a significant impact on both the IgG titer and kinetic parameters, and having a Body Mass Index (BMI) above the overweight threshold was associated with an impaired immune response. Overall, the heterologous ChAd/BNT vaccination may offer longer-lasting protection against SARS-CoV-2 than homologous vaccination strategies.

04 Jan 2012·Science translational medicineQ1 · MEDICINE

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

Q1 · MEDICINE

Article

Author: Colloca, Stefano ; Grazioli, Fabiana ; O’Hara, Geraldine A. ; Ammendola, Virginia ; Naddeo, Mariarosaria ; Cirillo, Agostino ; Cortese, Riccardo ; Smith, Kira ; Nicosia, Alfredo ; Sparacino, Angela ; Klenerman, Paul ; Esposito, Maria Luisa ; Barnes, Eleanor ; Bartiromo, Marta ; Ewer, Katie J. ; Siani, Loredana ; Kurioka, Ayako ; Capone, Stefania ; Folgori, Antonella ; Ambrosio, Maria ; Bliss, Carly ; Hill, Adrian V. S. ; Meola, Annalisa ; Traboni, Cinzia ; Anagnostou, Nicholas

Simian adenoviruses screened from wild-derived candidates can prime T cell responses in man and may serve as new vaccine vector candidates.

100 Deals associated with ChAd-triCoV/Mac(McMaster University)

Login to view more data